GOSS - Gossamer Bio - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

167.4M

Cash

162.1M

Avg Qtr Burn

-43.99M

Short % of Float

11.54%

Insider Ownership

5.40%

Institutional Own.

90.37%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details Rare diseases, Pulmonary arterial hypertension, Lung disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB004 (Oral HIF-1α stabilizer) Details Ulcerative colitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB1275 (Oral CD11b modulator) Details Solid tumor/s, Esophageal cancer, Cancer, Gastric cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB001 (Oral DP2 Antagonist) Details Asthma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.